Asa Nordling
Overview
Explore the profile of Asa Nordling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
486
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Riet S, Julien A, Atanasov A, Nordling A, Ingelman-Sundberg M
Hepatol Commun
. 2024 Feb;
8(3).
PMID: 38358377
Background: The prevalence of NAFLD is rapidly increasing. NAFLD can progress to NASH, fibrosis, cirrhosis, and HCC, which will soon become the main causes of liver transplantation. To date, no...
2.
Redensek Trampuz S, van Riet S, Nordling A, Ingelman-Sundberg M
Sci Rep
. 2024 Jan;
14(1):1396.
PMID: 38228622
Non-alcoholic steatohepatitis (NASH) is a major health problem leading to liver fibrosis and hepatocellular carcinoma, among other diseases, and for which there is still no approved drug treatment. Previous studies...
3.
Kloditz K, Tewolde E, Nordling A, Ingelman-Sundberg M
Clin Pharmacol Ther
. 2023 Jun;
114(3):673-685.
PMID: 37307233
During systemic inflammation, pro-inflammatory cytokines alter metabolism and transport of drugs affecting the clinical outcome. We used an in vivo like human 3D liver spheroid model to study the effects...
4.
Redensek Trampuz S, van Riet S, Nordling A, Ingelman-Sundberg M
Cells
. 2023 Jan;
12(2).
PMID: 36672237
Connective tissue growth factor (CTGF) is involved in the regulation of extracellular matrix (ECM) production. Elevated levels of CTGF can be found in plasma from patients with liver fibrosis and...
5.
Hendriks D, Vorrink S, Smutny T, Sim S, Nordling A, Ullah S, et al.
Clin Pharmacol Ther
. 2020 Apr;
108(4):844-855.
PMID: 32320483
Cytochrome P450 (CYP) 3A4 induction is an important cause of drug-drug interactions, making early identification of drug candidates with CYP3A4 induction liability in drug development a prerequisite. Here, we present...
6.
Hurrell T, Kastrinou-Lampou V, Fardellas A, Hendriks D, Nordling A, Johansson I, et al.
Cells
. 2020 Apr;
9(4).
PMID: 32295224
Non-alcoholic fatty liver disease affects approximately one billion adults worldwide. Non-alcoholic steatohepatitis (NASH) is a progressive disease and underlies the advancement to liver fibrosis, cirrhosis, and hepatocellular carcinoma, for which...
7.
Lauschke V, Nordling A, Zhou Y, Fontalva S, Barragan I, Ingelman-Sundberg M
Pharmacogenomics
. 2019 Oct;
20(15):1085-1092.
PMID: 31588878
Recently, it was published that CYP3A5 contributes to chemotherapeutic drug resistance in a wide range of solid tumors, including hepatocellular carcinoma. However, is highly polymorphic and 90% of Caucasians are...
8.
Kozyra M, Johansson I, Nordling A, Ullah S, Lauschke V, Ingelman-Sundberg M
Sci Rep
. 2018 Sep;
8(1):14297.
PMID: 30250238
Non-alcoholic fatty liver disease (NAFLD) has emerged as a public health concern as reflected in its widespread distribution in the general population. Yet, treatment options are scarce which is at...
9.
Lauschke V, Vorrink S, Moro S, Rezayee F, Nordling A, Hendriks D, et al.
Hepatology
. 2016 Aug;
64(5):1743-1756.
PMID: 27532775
Conclusion: miRNAs are important drivers of hepatic dedifferentiation, and our results provide valuable information regarding the mechanisms behind liver regeneration and possibilities to inhibit dedifferentiation in vitro. (Hepatology 2016;64:1743-1756).
10.
Bell C, Hendriks D, Moro S, Ellis E, Walsh J, Renblom A, et al.
Sci Rep
. 2016 May;
6:25187.
PMID: 27143246
Liver biology and function, drug-induced liver injury (DILI) and liver diseases are difficult to study using current in vitro models such as primary human hepatocyte (PHH) monolayer cultures, as their...